Pre-Exposure Prophylaxis (PrEP), 1% tenofovir (TFV) vaginal gel has failed in clinical trials. To improve TFV efficacy in vaginal gel, we formulated tenofovir disoproxil fumarate (TDF) nanoparticles (NPs) in a thermosensitive (TMS) gel (TDF-NPs-TMS gel). TDF NPs were fabricated using Poly Lactic-co-Glycolic Acid (PLGA) polymer and an ion-pairing agent by oil-in-water emulsification. Efficacy of TDF-NPs-TMS gel was tested in humanized-bone marrow-liver-thymus (BLT) (hu-BLT) mice.Hu-BLT mice grouped as treatment (Rx; n=15) were administered TDF-NPs-TMS gel intravaginally having TDF at 0.1%, 0.5%, and 1% (w/v) concentration whereas control (Ctr; n=8) group received blank TMS gel. All Rx mice (0.1% (n=4), 0.5% (n=6) and 1% (n=5)) were vaginally challenged with two transmitted/founder (T/F) HIV-1 viruses (5x10(5)TCID50). Rx mice were challenged at 4 h (0.1%), 24 h (0.5%), and 7-days (1%) post-treatment (PT) and Ctr mice challenged at 4 h PT, respectively. Blood was drawn weekly for 4 weeks post-inoculation (PI) for plasma viral load (pVL) using qRT-PCR. Ctr mice had positive pVL within 2 weeks PI. Rx mice challenged at 4 h and 24 h showed 100% protection and no detectable pVL throughout the 4 weeks of follow-up (p=0.009; Mantel-Cox test). Mice challenged at 7 days were HIV-1 positive at 14 days PI. Further, HIV-1 viral RNA (vRNA) in vaginal and spleen tissues of Rx group mice with negative pVL were examined using in-situ hybridization (ISH) technique. vRNA was negative in all Rx mice studied.The present studies elucidate TDF-NPs-TMS gel as a long acting, coitus-independent HIV-1 vaginal protection modality.